NCT02711137 2025-10-21Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated137 enrolled 31 charts
NCT02465528 2019-12-27Ceritinib Rare Indications Study in ALK+ TumorsNovartisPhase 2 Terminated22 enrolled 16 charts